Greenspring Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Greenspring Associates’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,573,357	Closed	-$31M	–	12
2021 Q2	$31M	Hold	1,573,357	–	–	2.1%	5
2021 Q1	$45.7M	Hold	1,573,357	–	–	36.38%	1
2020 Q4	$47.7M	Hold	1,573,357	–	–	61.89%	1
2020 Q3	$25M	Hold	1,573,357	–	–	38.95%	1
2020 Q2	$31.1M	Hold	1,573,357	–	–	19.06%	2
2020 Q1	$19.4M	Hold	1,573,357	–	–	8.03%	4
2019 Q4	$29.1M	Hold	1,573,357	–	–	7.67%	5
2019 Q3	$21.8M	Hold	1,573,357	–	–	6.61%	5
2019 Q2	$23M	Buy	+1,573,357	New	+$23M	11.86%	2

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Greenspring Associates's NGM Position: Q3 2021 in Review

Greenspring Associates sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2021, closing a stake of 1,573,357 shares — an estimated $31M sold.

Greenspring Associates first reported a position in NGM in Q2 2019 and held it in 9 quarters. The position peaked at $47.7M in Q4 2020. 120 funds tracked by Wall St. Rank hold NGM as of Q3 2021.

Greenspring Associates reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Greenspring Associates sold 1,573,357 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $31M.
Greenspring Associates first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
Greenspring Associates's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $47.7M in Q4 2020.
120 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Greenspring Associates's 13F filing for Q3 2021.